Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of misleading statements and failure to disclose critical information regarding its prostate cancer therapeutic candidates, leading to significant investor losses [3][4][5]. Group 1: Allegations and Legal Actions - The complaint alleges that Telix and its executives materially overstated the progress of their prostate cancer therapeutic candidates and the quality of their supply chain, resulting in misleading statements about the company's business and prospects [3]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, which caused the price of Telix's American Depositary Shares to drop by over 13% in two trading sessions [4]. - Following the disclosure of a Complete Response Letter from the FDA on August 28, 2025, regarding deficiencies in the Chemistry, Manufacturing, and Controls package for TLX250-CDx, Telix's ADS price fell by more than 21% over two trading sessions [5]. Group 2: Class Action Details - The deadline for investors to seek the role of lead plaintiff in the federal securities class action against Telix is January 9, 2026, with the lead plaintiff being the investor with the largest financial interest who is typical of class members [6]. - Faruqi & Faruqi encourages anyone with information regarding Telix's conduct, including whistleblowers and former employees, to contact the firm [6].
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals